China NMPA Product Recall - Philips HeartStart XL+ Defibrillator/Monitor

On November 15, 2019, the National Medical Products Administration (NMPA) published a voluntary recall initiated by Philips (China) Investment Co., Ltd. regarding its HeartStart XL+ defibrillator/monitor. The recall was prompted by potential unexpected device behavior, specifically a malfunctioning energy selection knob. This critical component defect could lead to the device failing to activate, failing to execute the selected function, or delivering electrical shocks at an incorrect energy level different from the user's selection. Such malfunctions pose significant patient risks, including delays in urgent medical treatment or a complete failure to deliver intended therapy.

The recall, classified as Class II, affects defibrillator/monitors manufactured by Philips (China) Investment Co., Ltd. and registered under the Shanghai Food and Drug Administration. While specific inspection dates are not detailed in this announcement, the company proactively reported the issue through an internal recall document (FCO86100208). As a required action under this regulatory framework, Philips (China) Investment Co., Ltd. is voluntarily recalling the affected devices. Full details concerning specific product models, specifications, and batch numbers are provided in the accompanying "Medical Device Recall Event Report Form," which stakeholders are advised to consult for comprehensive information. This action highlights the importance of maintaining medical device safety standards and regulatory compliance.